Reviews & Editorials on I-SPY 2

The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster. At the heart of the I-SPY program is the ground-breaking I-SPY 2 platform trial for neoadjuvant treatment of locally advanced breast cancer.
Play Video
Play Video

Reinventing clinical trials

Laura Esserman’s 2015 lecture at ‘Exponential Medicine’ discussed the re-engineering of clinical trials, inspired by the insights of late Intel CEO Andy Grove into the differences between development in the semiconductor industry and healthcare.

Length: 26:50 min

Play Video

I-SPY 2 and other platform trials

I-SPY2 Principal Statistician Don Berry of Berry Consultants explains the history and fundamentals of platform trial models and how they are changing drug development in breast cancer and beyond.

Length: 31:52 min

Play Video

I-SPY Clinical Trials:
An interview with Dr. Laura Esserman

The ground-breaking I-SPY 2 trial of neoadjuvant treatment for locally advanced breast cancer established a new benchmark for efficiency of phase II clinical trials. Widely regarded as a pioneer of the ‘platform’ trial, I-SPY 2’s success continues to be a major influence on the development of next-generation trial designs in oncology and beyond.

Play Video

Changing strategies in the 'war on cancer'

Dr. Angela DiMichele, Professor of Medicine and Epidemiology at the Perelman School of Medicine at the University of Pennsylvania and I-SPY 2 Site Operations Working Group Chair discusses the innovations of I-SPY 2 and testing of new antibody-drug conjugates.

Length: 34:32 min

Play Video

How to design an adaptive trial - Lessons learned, so far

How do you design an adaptive trial? Scott Berry one of the adaptive trial experts at Berry Consultants presents a recipe for designing a high-impact adaptive trial, secret sauce included.

Length: 38:18 min

Contact Us
Investigators Portal
QLHC in the News
Working at QL
Contact Us